Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up to 106.14 million shares, equivalent to 10% of Ascletis Pharma’s issued share capital (excluding treasury stock) as of the AGM date.

The board has earmarked up to HK$300 million of internal funds for open-market repurchases. Proceeds from the 2018 global offering, the 25 August 2025 top-up placement, and the 10 February 2026 new-share placement will not be used.

Pricing will follow Hong Kong Listing Rules, capping any repurchase price at no more than 5% above the average closing price over the five trading days preceding each transaction. Repurchases will proceed only if they do not materially impair working-capital adequacy, and public float requirements will be maintained. Repurchased shares may be cancelled, held as treasury shares, sold, or transferred at the board’s discretion.

As of the announcement date, no shares have been bought back under the mandate. The company emphasizes that execution timing, volume, and pricing remain subject to market conditions and board discretion.